LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.
The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.
AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.
Share this article Amylyx will spend the next eight weeks reviewing the data with the FDA and ALS community. Image credit: Shutterstock / David Herraez
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, all. Damian
To encourage robust, good-faith discussion about difficult issues, STAT publishes selected Letters to the Editor received in response to First Opinion essays. Submit a Letter